BR112012024587A2 - compostos de purina usados como agonistas de cb2 - Google Patents

compostos de purina usados como agonistas de cb2

Info

Publication number
BR112012024587A2
BR112012024587A2 BR112012024587A BR112012024587A BR112012024587A2 BR 112012024587 A2 BR112012024587 A2 BR 112012024587A2 BR 112012024587 A BR112012024587 A BR 112012024587A BR 112012024587 A BR112012024587 A BR 112012024587A BR 112012024587 A2 BR112012024587 A2 BR 112012024587A2
Authority
BR
Brazil
Prior art keywords
agonists
compounds used
purine compounds
purine
compound
Prior art date
Application number
BR112012024587A
Other languages
English (en)
Inventor
Sean Patrick Hollinshead
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112012024587A2 publication Critical patent/BR112012024587A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

compostos de purina usados como agonistas de cb2 um composto da fórmula (l) e composições farmacêuticas para o tratamento da dor
BR112012024587A 2010-03-31 2011-03-30 compostos de purina usados como agonistas de cb2 BR112012024587A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31953210P 2010-03-31 2010-03-31
PCT/US2011/030412 WO2011123482A1 (en) 2010-03-31 2011-03-30 Purine compounds used as cb2 agonists

Publications (1)

Publication Number Publication Date
BR112012024587A2 true BR112012024587A2 (pt) 2016-05-31

Family

ID=43902609

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024587A BR112012024587A2 (pt) 2010-03-31 2011-03-30 compostos de purina usados como agonistas de cb2

Country Status (12)

Country Link
US (1) US8710063B2 (pt)
EP (1) EP2552916B1 (pt)
JP (1) JP5674918B2 (pt)
KR (1) KR101432411B1 (pt)
CN (1) CN102803263B (pt)
AU (1) AU2011235290B2 (pt)
BR (1) BR112012024587A2 (pt)
CA (1) CA2795006C (pt)
EA (1) EA020565B1 (pt)
ES (1) ES2481867T3 (pt)
MX (1) MX2012011164A (pt)
WO (1) WO2011123482A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067943B2 (en) 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
WO2005069865A2 (en) 2004-01-13 2005-08-04 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds

Also Published As

Publication number Publication date
EP2552916B1 (en) 2014-05-21
AU2011235290A1 (en) 2012-09-06
CN102803263B (zh) 2014-12-17
JP5674918B2 (ja) 2015-02-25
EP2552916A1 (en) 2013-02-06
JP2013523755A (ja) 2013-06-17
ES2481867T3 (es) 2014-07-31
EA201270727A1 (ru) 2013-01-30
MX2012011164A (es) 2012-11-12
KR101432411B1 (ko) 2014-08-20
US20120329809A1 (en) 2012-12-27
CN102803263A (zh) 2012-11-28
KR20130006642A (ko) 2013-01-17
US8710063B2 (en) 2014-04-29
EA020565B1 (ru) 2014-12-30
WO2011123482A1 (en) 2011-10-06
AU2011235290B2 (en) 2013-12-05
CA2795006C (en) 2014-05-13
CA2795006A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
CO6710897A2 (es) Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
ECSP13012499A (es) Nuevos compuestos
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CR20130045A (es) Compuestos terapéuticos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
PA8851501A1 (es) Compuestos purina
UY31065A1 (es) Heterociclos ciclicos
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
EA201100037A1 (ru) Органические соединения
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
CO6480975A2 (es) Mimetico de smac
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
HN2010001920A (es) Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa
UY33539A (es) Compuestos químicos alk
BR112012024586A2 (pt) compostos de purina
CU20090139A7 (es) Nuevo procedimiento de síntesis de agomelatina
CO6721019A2 (es) Quinazolincarboxamida azetidinas
CY1111807T1 (el) Παραγωγα βενζοθειαζεπινης και η χρηση τους ως ρυθμιστων των υποδοχεων ampα και nmda
CU20090137A7 (es) Nuevo procedimiento de síntesis de la agomelatina
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]